Oncocyte to Participate in the 5th Annual Lake Street Capital Markets Best Ideas Growth Conference

Rhea-AI Summary

Oncocyte Corporation (Nasdaq: OCX) announced participation in the 5th Annual Lake Street Capital Markets Best Ideas Growth Conference on September 14, 2021. Management will engage in one-on-one and group investor meetings aimed at presenting the company's precision diagnostics and monitoring capabilities for cancer. Oncocyte focuses on improving patient outcomes through proprietary tests like DetermaRx™ and DetermaIO™, which aid in early detection and treatment decisions in oncology. Interested investors can contact Lake Street Capital Markets for meeting arrangements.

IRVINE, Calif., Sept. 07, 2021 (GLOBE NEWSWIRE) -- Oncocyte Corporation (Nasdaq: OCX), a precision diagnostics and monitoring company with the mission to improve patient outcomes by providing clear insights that inform critical decisions in the diagnosis, treatment, and monitoring of cancer, today announced that management will participate in one-on-one and group investor meetings at the 5^th Annual Lake Street Capital Markets Best Ideas Growth Conference.

Conference Details:

5^th Annual Lake Street Capital Markets Best Ideas Growth Conference
Date: Tuesday, September 14, 2021
Format: 1x1 and Group Investor Meetings

Investors interested in meeting with the Oncocyte management team during these events should contact their respective Lake Street Capital Markets representatives.

About Oncocyte Corporation
Oncocyte is a precision diagnostics and monitoring company with the mission to improve patient outcomes by providing clear insights that inform critical decisions in the diagnosis, treatment, and monitoring of cancer. The Company, through its proprietary tests and pharmaceutical services business, aims to help save lives by accelerating the diagnosis of cancer and advancing cancer care. The Company’s tests are designed to help provide clarity and confidence to physicians and their patients at every stage. DetermaRx™ identifies early-stage lung cancer patients who are at high risk for cancer recurrence and who may benefit from adjuvant chemotherapy. DetermaIO™, a gene expression test currently used as a research-use only tool, assesses the tumor microenvironment to predict response to immunotherapies. The Company’s pipeline of tests in development also includes DetermaTx™, which will assess mutational status of a tumor, blood-based monitoring test DetermaCNI™, and long-term recurrence monitoring test DetermaMx™. In addition, Oncocyte’s pharmaceutical services provide companies that are developing new cancer treatments a full suite of molecular testing services to support the drug development process.

DetermaRx™, DetermaIO™, DetermaTx™, DetermaCNI™ and DetermaMx™ are trademarks of Oncocyte Corporation.

Investor Contact
Bob Yedid
LifeSci Advisors, LLC
646-597-6989
bob@lifesciadvisors.com

FAQ

What is the date of the 5th Annual Lake Street Capital Markets Best Ideas Growth Conference for Oncocyte Corporation?

The conference is scheduled for September 14, 2021.

What type of meetings will Oncocyte Corporation participate in at the conference?

Oncocyte will participate in one-on-one and group investor meetings.

What is the mission of Oncocyte Corporation?

Oncocyte aims to improve patient outcomes by providing insights for cancer diagnosis, treatment, and monitoring.

What are some of the tests developed by Oncocyte Corporation?

Oncocyte has developed tests like DetermaRx™, DetermaIO™, and has a pipeline that includes DetermaTx™, DetermaCNI™, and DetermaMx™.

How does DetermaRx™ assist in cancer treatment?

DetermaRx™ identifies early-stage lung cancer patients at high risk for recurrence who may benefit from chemotherapy.